| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H27FN4O2 |
| Molecular Weight | 434.5059 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=CC=C1N2CCN(CCN(C(=O)C3=CC=C(F)C=C3)C4=NC=CC=C4)CC2
InChI
InChIKey=YJZYDPRMWYWYCG-UHFFFAOYSA-N
InChI=1S/C25H27FN4O2/c1-32-23-7-3-2-6-22(23)29-17-14-28(15-18-29)16-19-30(24-8-4-5-13-27-24)25(31)20-9-11-21(26)12-10-20/h2-13H,14-19H2,1H3
| Molecular Formula | C25H27FN4O2 |
| Molecular Weight | 434.5059 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
4-FLUORO-N-{2-[4-(2-METHOXYPHENYL)-1-PIPERAZINYL]ETHYL}-N-(2-PYRIDINYL)BENZAMIDE HYDROCHLORIDE (p-MPPF) is a potent and selective 5-HT1A receptor antagonist. Animal experiments and clinical trials have shown that radiolabeled [(18)F]p-MPPF can be used for 5-hydroxytryptamine(1A) (5-HT(1A)) receptor imaging.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 3.3 nM [Ki] |